PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...

PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...

The American Journal of Managed Care® discussed an indirect comparison of andexanet alfa and prothrombin complex concentrate therapy with Alexander T. Cohen, MBBS, MSc, MD, Guy’s and St Thomas’ ...

Credit: Getty Images. Balfaxar is a non-activated 4 factor prothrombin complex concentrate containing vitamin K-dependent factors. The Food and Drug Administration (FDA) has approved Balfaxar ® ...

Early administration of 4-factor prothrombin complex concentrate (4F-PCC) was of no benefit to patients with trauma at risk of massive transfusion, the randomized PROCOAG trial from France showed.

For patients who experience excessive bleeding during cardiac surgery, four-factor prothrombin complex concentrate (4F-PCC), a blood product that contains clotting factors, is significantly more ...

About The Study: In this unblinded randomized clinical trial, prothrombin complex concentrate had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring ...

What is Kcentra®/4-factor Prothrombin Complex Concentrate? Kcentra® (4-factor Prothrombin Complex Concentrate), is a blood clotting factor replacement product. It contains clotting factors II, VII, IX ...

Credit: Octapharma. Balfaxar is a human plasma-derived, purified, virus inactivated and nanofiltered non-activated prothrombin complex concentrate. Balfaxar ® (prothrombin complex concentrate, ...

The Center for Injury Science (CIS) at UAB has partnered with CSL Behring to support the management of one of the largest ever trauma clinical trials. The Trauma and Prothrombin Complex Concentrate ...